Takeda Pharmaceutical Company Limited
NYSE:TAK · New York Stock Exchange
+$0.18 today
Vol 2.05M · Avg 3.08M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $597.6B |
| Receivables | $880.1B |
| Inventory | $1.4T |
| Other Current | $223.4B |
| Total Current Assets | $3.1T |
| PP&E (Net) | $2.1T |
| Goodwill | $5.8T |
| Intangible Assets | $3.4T |
| Long-term Investments | $450.7B |
| Tax Assets | $490.0B |
| Other Non-current | $77.3B |
| Total Non-current Assets | $12.4T |
| Total Assets | $15.5T |
Analysis
Selected assets total $15.5T for Latest. The largest visible component is Goodwill at $5.8T, about 37.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $597.6B +55.2% | $385.1B -15.9% | $457.8B -14.2% | $533.5B -37.2% | $849.7B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 -100.0% | $20.5B +35.7% | $15.1B -25.2% | $20.2B -20.3% | $25.3B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $880.1B +21.4% | $725.3B +4.0% | $697.6B +2.3% | $681.7B -5.9% | $724.4B | $533.8M | $399.4M | -$1.7B |
| Inventory | $1.4T +15.2% | $1.2T +0.6% | $1.2T +22.6% | $986.5B +15.6% | $853.2B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $223.4B +29.2% | $173.0B -2.9% | $178.2B +1.2% | $176.1B +24.8% | $141.1B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $3.1T +23.1% | $2.5T -1.5% | $2.6T +6.7% | $2.4T -7.5% | $2.6T | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $2.1T +8.2% | $2.0T -1.1% | $2.0T +17.7% | $1.7T +6.9% | $1.6T | $1.2B | $1.5B | $687.8M |
| Goodwill | $5.8T +9.6% | $5.3T -1.6% | $5.4T +12.9% | $4.8T +8.7% | $4.4T | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $3.4T -5.4% | $3.6T -15.0% | $4.3T +0.1% | $4.3T +11.8% | $3.8T | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $450.7B +24.5% | $361.9B -16.0% | $430.6B +13.7% | $378.9B +14.8% | $330.1B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $490.0B +32.2% | $370.7B -5.9% | $393.9B +7.6% | $366.0B +1.0% | $362.5B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $77.3B +10.0% | $70.3B +37.2% | $51.2B -19.1% | $63.3B -23.3% | $82.6B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $12.4T +5.9% | $11.7T -6.6% | $12.6T +8.6% | $11.6T +9.2% | $10.6T | -$15.3B | $14.8B | $11.3B |
| Total Assets | $15.5T +8.9% | $14.2T -5.7% | $15.1T +8.2% | $14.0T +5.9% | $13.2T | $13.3B | $11.9B | $10.6B |
| Account Payables | $493.5B +60.0% | $308.4B -3.6% | $320.0B +4.1% | $307.5B +3.9% | $295.9B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $514.4B -6.3% | $548.9B +49.5% | $367.3B +8.1% | $339.6B +66.5% | $204.0B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $109.9B -52.7% | $232.4B +15.7% | $200.9B | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $1.3T -1.1% | $1.3T +4.7% | $1.3T +2.2% | $1.3T +3.0% | $1.2T | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $2.4T -2.7% | $2.5T +8.4% | $2.3T -6.8% | $2.5T +15.7% | $2.1T | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $4.4T +10.6% | $4.0T -11.4% | $4.5T +10.7% | $4.0T -2.4% | $4.1T | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $26.9B -23.4% | $35.2B -69.1% | $113.8B -58.0% | $270.6B -40.1% | $451.5B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $856.0B +6.4% | $804.4B -13.6% | $931.4B +15.3% | $807.8B +6.9% | $755.8B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $5.3T +9.7% | $4.8T -13.0% | $5.5T +7.8% | $5.1T -4.3% | $5.3T | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $7.7T +5.5% | $7.3T -6.7% | $7.8T +3.0% | $7.6T +1.4% | $7.5T | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.7T +0.5% | $1.7T +1.1% | $1.7T +0.0% | $1.7T +0.0% | $1.7T | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $1.1T -10.6% | $1.2T -14.6% | $1.4T -9.7% | $1.5T +4.2% | $1.5T | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $3.3T +40.7% | $2.4T -6.3% | $2.5T +66.4% | $1.5T +61.4% | $934.2B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 +100.0% | -$1.0M -200.0% | $1.0M | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $1.2B +35.6% | $895.0M +20.8% | $741.0M +35.0% | $549.0M +8.9% | $504.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $7.8T +12.6% | $6.9T -4.6% | $7.3T +14.5% | $6.4T +11.8% | $5.7T | $9.1B | $7.7B | $3.3B |
| Total Debt | $4.9T +8.6% | $4.5T -6.8% | $4.8T +10.5% | $4.4T +0.8% | $4.3T | $724.2M | $410.6M | $399.4M |
| Net Debt | $4.3T +4.2% | $4.1T -5.8% | $4.4T +14.0% | $3.8T +10.1% | $3.5T | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.27B
Becton, Dickinson and Company
NYSE:BDX
$52.17B
Edwards Lifesciences Corporation
NYSE:EW
$50.20B
Haleon plc
NYSE:HLN
$39.49B
Agilent Technologies, Inc.
NYSE:A
$35.96B
Alcon Inc.
NYSE:ALC
$31.49B
IQVIA Holdings Inc.
NYSE:IQV
$27.93B
ResMed Inc.
NYSE:RMD
$27.22B
Veeva Systems Inc.
NYSE:VEEV
$24.76B
Insmed Incorporated
NASDAQ:INSM
$20.55B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does TAK have?
Takeda Pharmaceutical Company Limited (TAK) reported $597.63B in cash and equivalents in fiscal 2025.
How much debt does TAK carry?
Takeda Pharmaceutical Company Limited (TAK) reported $4.90T of total debt, with net debt of $4.31T.
Explore More
Continue the stock analysis
Jump to another research area for this company.